Setting

North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity

Published: 30 Jun 2021 | Report Code: 10248049 | Pages: 78

North America amyotrophic lateral sclerosis treatment market is expected to grow by 5.0% annually in the forecast period and reach $270.6 million by 2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies. Highlighted with 21 tables and 31 figures, this 78-page report “North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire North America amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country. Based on Treatment Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Medication o Riluzole (Rilutek) o Radicava (Edaravone) o Tiglutik (Thickened Riluzole) o Nuedexta • Stem Cell Therapy • Other Treatments Based on ALS Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Sporadic ALS • Familial ALS Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Other Distribution Channels Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AB Science SA Amylyx Pharmaceuticals Inc. Biogen Inc. Biohaven Pharmaceutical Holding Co., Ltd. BrainStorm Cell Limited Corestem, Inc. F.Hoffmann-La Roche AG Ionis Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Otsuka Pharmaceutical Co., Ltd. Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	5
1.1 Industry Definition and Research Scope	5
1.1.1 Industry Definition	5
1.1.2 Research Scope	6
1.2 Research Methodology	9
1.2.1 Overview of Market Research Methodology	9
1.2.2 Market Assumption	10
1.2.3 Secondary Data	10
1.2.4 Primary Data	10
1.2.5 Data Filtration and Model Design	11
1.2.6 Market Size/Share Estimation	12
1.2.7 Research Limitations	13
1.3 Executive Summary	14
2 Market Overview and Dynamics	16
2.1 Market Size and Forecast	16
2.1.1 Impact of COVID-19 on World Economy	17
2.1.2 Impact of COVID-19 on the Market	19
2.2 Major Growth Drivers	21
2.3 Market Restraints and Challenges	25
2.4 Emerging Opportunities and Market Trends	28
2.5 Porter’s Fiver Forces Analysis	32
3 Segmentation of North America Market by Treatment Type	36
3.1 Market Overview by Treatment Type	36
3.2 Medication	38
3.3 Stem Cell Therapy	40
3.4 Other Treatments	41
4 Segmentation of North America Market by ALS Type	42
4.1 Market Overview by ALS Type	42
4.2 Sporadic ALS	44
4.3 Familial ALS	45
5 Segmentation of North America Market by Distribution Channel	46
5.1 Market Overview by Distribution Channel	46
5.2 Hospital Pharmacies	48
5.3 Retail Pharmacies	49
5.4 Online Pharmacies	50
5.5 Other Distribution Channels	51
6 North America Market 2020-2027 by Country	52
6.1 Overview of North America Market	52
6.2 U.S.	55
6.3 Canada	58
6.4 Mexico	60
7 Competitive Landscape	62
7.1 Overview of Key Vendors	62
7.2 New Product Launch, Partnership, Investment, and M&A	65
7.3 Company Profiles	66
AB Science SA	66
Amylyx Pharmaceuticals Inc.	68
Biogen Inc.	69
Biohaven Pharmaceutical Holding Co., Ltd.	70
BrainStorm Cell Limited	71
Corestem, Inc.	72
F.Hoffmann-La Roche AG	73
Ionis Pharmaceuticals, Inc.	74
Mitsubishi Tanabe Pharma Corporation	75
Otsuka Pharmaceutical Co., Ltd.	76
Sun Pharmaceutical Industries Ltd.	77
RELATED REPORTS	78
List Of Tables

Table 1.  Snapshot of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027	15
Table 2. Growth Rate of World GDP, 2020-2022	18
Table 3.  Main Product Trends and Market Opportunities in North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market	28
Table 4. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	36
Table 5. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn	39
Table 6. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	42
Table 7. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	46
Table 8. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	53
Table 9. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	57
Table 10. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	57
Table 11. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	57
Table 12. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	59
Table 13. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	59
Table 14. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	59
Table 15. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	61
Table 16. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	61
Table 17. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	61
Table 18. AB Science SA: Company Snapshot	66
Table 19. AB Science SA: Business Segmentation	66
Table 20. AB Science SA: Product Portfolio	67
Table 21. AB Science SA: Revenue, 2017-2019, $ mn	67
List Of Figures

Figure 1. Research Method Flow Chart	9
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	12
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027	14
Figure 4. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	16
Figure 5. Impact of COVID-19 on Business	19
Figure 6. Primary Drivers and Impact Factors of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market	21
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	24
Figure 8. Primary Restraints and Impact Factors of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market	25
Figure 9. Investment Opportunity Analysis	29
Figure 10. Porter’s Fiver Forces Analysis of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market	32
Figure 11. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue	36
Figure 12. Contribution to North America 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%)	37
Figure 13. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn	38
Figure 14. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn	40
Figure 15. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn	41
Figure 16. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue	42
Figure 17. Contribution to North America 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%)	43
Figure 18. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn	44
Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn	45
Figure 20. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue	47
Figure 21. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)	47
Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn	48
Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn	49
Figure 24. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn	50
Figure 25. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn	51
Figure 26. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	53
Figure 27. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	54
Figure 28. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	56
Figure 29. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	58
Figure 30.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Mexico, 2017-2027, $ mn	60
Figure 31. Growth Stage of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period	62
Key Players (this may not be a complete list and extra companies can be added upon request): 
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)